2020 Pediatric Rheumatology Symposium

April 29-May 2, 2020

The 2020 Pediatric Rheumatology Symposium, originally scheduled for April 29 – May 2, was postponed due to COVID-19; therefore, abstracts were not presented as scheduled.

View by Number View by Title View Sessions

View by Date

Friday, May 1, 2020

5:00PM-6:00PM: Abstract Number: 098

Early Treatment with Anakinra in Systemic Juvenile Idiopathic Arthritis

Poster Session 2

5:00PM-6:00PM: Abstract Number: 177

Educational Outcomes in a Young-Adult Cohort of Patients with Childhood Onset Systemic Lupus Erythematosus (SLE)

Poster Session 2

5:00PM-6:00PM: Abstract Number: 158

Genetics of Age at Diagnosis in Childhood-Onset Systemic Lupus Erythematosus

Poster Session 2

5:00PM-6:00PM: Abstract Number: 178

HEADSS and Shoulders, Knees and Toes: Improving Sexual Orientation and Gender Identity Screening in the Pediatric Rheumatology Clinic

Poster Session 2

5:00PM-6:00PM: Abstract Number: 176

Implementation of an Abbreviated Neuropsychology Screening Protocol for Patients Diagnosed with Childhood-onset Systemic Lupus Erythematosus

Poster Session 2

5:00PM-6:00PM: Abstract Number: 102

Implications of Positive Tests for ANCA in a Pediatric Population

Poster Session 2

5:00PM-6:00PM: Abstract Number: 174

Improving Hospital Discharge Instructions for Pediatric Rheumatology Patients

Poster Session 2

5:00PM-6:00PM: Abstract Number: 109

Incidence, Contributing Factors, and Impact of Diagnostic Delay in Juvenile Idiopathic Arthritis: Analysis of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry

Poster Session 2

5:00PM-6:00PM: Abstract Number: 084

Kawasaki Disease Shock Syndrome: A Single Center Cohort

Poster Session 2

5:00PM-6:00PM: Abstract Number: 096

Medication Adherence in Adolescents and Young Adults with Childhood Onset SLE

Poster Session 2

5:00PM-6:00PM: Abstract Number: 156

Metabolic Profiling in Juvenile Dermatomyositis

Poster Session 2

5:00PM-6:00PM: Abstract Number: 104

Patients Perspectives on Living with a Systemic Autoinflammatory Disease: Impact on Quality of Life

Poster Session 2

5:00PM-6:00PM: Abstract Number: 155

Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) Is Characterized by a Novel Subset of Monocytes with Markers Associated with Crossing the Blood Brain Barrier (BBB)

Poster Session 2

5:00PM-6:00PM: Abstract Number: 091

Protracted Febrile Myalgia Findings on Magnetic Resonance Imaging

Poster Session 2

5:00PM-6:00PM: Abstract Number: 095

Pyoderma Gangrenosum Ulceration as a Presenting Feature of Pediatric Granulomatosis with Polyangiitis (GPA)

Poster Session 2

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].